Israeli multimodality vendor Elscint received Food and Drug Administration510(k) clearance last month for SeleCT/SP, an entry-level spiralCT scanner designed for cost-conscious customers (SCAN 7/17/96).The compact scanner, which was introduced at last
Israeli multimodality vendor Elscint received Food and Drug Administration510(k) clearance last month for SeleCT/SP, an entry-level spiralCT scanner designed for cost-conscious customers (SCAN 7/17/96).The compact scanner, which was introduced at last year's RadiologicalSociety of North America meeting, uses a unique short-geometrydesign to save space. Elscint plans to begin international deliveriesof SeleCT/SP in the third quarter, with U.S. shipments startingin the fourth quarter.
In other SeleCT/SP news, Elscint signed an agreement with BirlaMedical Technologies of India in which BMT will assemble SeleCT/SPunder license for sale in the Indian market. BMT expects to beginassembling SeleCT/SP scanners in a factory near New Delhi laterthis year.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.